secwatch.observer — SEC 8-K summary
======================================

Issuer:     Humacyte, Inc. (HUMA)
CIK:        0001818382
Form:       8-K
Filed at:   2024-03-22T23:59:59+00:00
Accession:  0001818382-24-000034
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Humacyte BLA for HAV gets Priority Review; PDUFA Aug 10, 2024; Q4 net loss $25.1M
--------------------------------------------------------------------------------

- FDA accepted BLA for HAV with Priority Review in vascular trauma; PDUFA date August 10, 2024.
- Raised ~$43.1M net from public offering in March 2024; additional $20M draw from Oberland.
- Cash and equivalents $80.4M at Dec 31, 2023; net cash used $69.0M in 2023.
- No revenue in Q4 2023; R&D expenses $20.2M (up from $15.0M), net loss $25.1M.
- Full year 2023 net loss $110.8M vs $12.0M in 2022 due to non-cash remeasurement and higher expenses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818382/000181838224000034/0001818382-24-000034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818382/000181838224000034/huma-20240322.htm
  HTML page:      https://secwatch.observer/filing/0001818382-24-000034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer